Sign in
CompletedNo phase

Gender Differences in Switching From Smoking Regular Cigarettes to E-Cigarettes

Key facts

Who runs it
M.D. Anderson Cancer Center
Where
Houston, United StatesSee the site
Trial code
Status
Completed
People taking part
169 people enrolled
Started
2 Jun 2022
Ended
7 Jan 2026
Type of study
Interventional, 2 groups
Treatments tested
  • Nicotine Replacement
  • Questionnaire Administration
  • Electronic Cigarette
Record updated
28 January 2026

Who can take part

Age
21 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Aged 21 years or older
  • Reports being a daily or non-daily smoker (any self-reported smoking in the past 30 days)
  • Have an address where he/she can receive mail
  • Able to follow verbal and written instructions in English and complete all aspects of the study as determined by PI
  • Willing to have urine biospecimen samples taken, either in-home and returning them by mail, or in-person at an approved collection site
  • Willing to use tobacco-flavored study electronic cigarettes
  • Agrees to comply with all MD Anderson institutional policies related to COVID-19 screening prior to any in-person research visit
  • The individual agrees to not engage in study procedures or interactions with study personnel while operating a vehicle

Who cannot take part

  • Being pregnant, engaging in breast-feeding, or being of childbearing potential and engaging in sexual activity that could lead to pregnancy and is not protected by a medically acceptable, effective method of birth control while enrolled in the study, as determined by self-report. Medically acceptable contraceptives include: (1) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (2) barrier methods (such as a condom or diaphragm) used with a spermicide, or (3) an intrauterine device (IUD). Contraceptive measures sold for emergency use after unprotected sex are not acceptable methods for routine use
  • Uncontrolled or unstable medical condition (e.g., uncontrolled hypertension, angina, diabetes)
  • Individuals who report depressive symptoms in the moderately severe or severe range on the PHQ-9 (scores of 15 or above) or who report current suicidal ideation on the PHQ-9
  • Evidence of cognitive deficits or instability that would preclude reliable study participation
  • Considered by the investigator to be an unsuitable or unstable candidate (including but not limited to the following situation: unwilling or unable to comply with study procedures)
  • Individuals who reside in an area that is outside of our shipping company's area of operation or in a jurisdiction outside of our medical staff's licensure (if unable to attend in-person clinic visits) AND who decline or are unable to come in to clinic to provide necessary samples and/or collect study products

Where in United States

  • M D Anderson Cancer CenterHouston, United States

About the trial

What the trial wants to find out

This early phase I trial studies potential differences between men and women when switching from the use of combustible cigarettes to the National Institute on Drug Abuse's Standard Research E-Cigarette (SREC). Studying the differences between men and women may increase understanding about the effects of switching from smoking regular cigarettes to electronic cigarettes.

The 2 groups in the trial

  • E-Cig placebo dose followed by E-Cig nicotine doseTreatment being tested

    Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.

    Treatment: Nicotine Replacement, Questionnaire Administration, and Electronic Cigarette

  • E-Cig nicotine dose followed by E-Cig placebo doseTreatment being tested

    Participants will be instructed to smoke their usual brand cigarette as they normally would in weeks 1-2 (Phase I) and to use only the SREC (with or without nicotine) in weeks 3-4 (Phase II) and in weeks 5-6 (Phase III). Participant assignment to SREC type at Phases II and III will be counter-balanced within group, with half of men and women receiving the placebo SREC during Phase II and half during Phase III. Participants will attend 4 laboratory visits with study investigators for 3 hours each over 6 weeks of study participation.

    Treatment: Nicotine Replacement, Questionnaire Administration, and Electronic Cigarette

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Gender Differences in Standardized Research E-Cigarette (SREC) Product Use, Acceptability, Reinforcement, and Nicotine Dependence Symptoms
Publications
Record updated
28 January 2026